JOP20220030A1 - صيغ مضادة لـ c5 عالية التركيز - Google Patents

صيغ مضادة لـ c5 عالية التركيز

Info

Publication number
JOP20220030A1
JOP20220030A1 JOP/2022/0030A JOP20220030A JOP20220030A1 JO P20220030 A1 JOP20220030 A1 JO P20220030A1 JO P20220030 A JOP20220030 A JO P20220030A JO P20220030 A1 JOP20220030 A1 JO P20220030A1
Authority
JO
Jordan
Prior art keywords
formulations
high concentration
concentration anti
cemdisiran
ahus
Prior art date
Application number
JOP/2022/0030A
Other languages
English (en)
Inventor
Mayank Patel
Xiaolin Tang
Mary Kleppe
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of JOP20220030A1 publication Critical patent/JOP20220030A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

غير متوفر
JOP/2022/0030A 2019-08-16 2020-08-14 صيغ مضادة لـ c5 عالية التركيز JOP20220030A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962888086P 2019-08-16 2019-08-16
PCT/US2020/046314 WO2021034639A1 (en) 2019-08-16 2020-08-14 High concentration anti-c5 formulations

Publications (1)

Publication Number Publication Date
JOP20220030A1 true JOP20220030A1 (ar) 2023-01-30

Family

ID=72560889

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0030A JOP20220030A1 (ar) 2019-08-16 2020-08-14 صيغ مضادة لـ c5 عالية التركيز

Country Status (14)

Country Link
US (1) US20210046182A1 (ar)
EP (1) EP4013784A1 (ar)
JP (1) JP2022544589A (ar)
KR (1) KR20220047826A (ar)
CN (1) CN116782876A (ar)
AU (1) AU2020334880A1 (ar)
BR (1) BR112022002831A2 (ar)
CA (1) CA3145621A1 (ar)
CL (1) CL2022000340A1 (ar)
CO (1) CO2022001097A2 (ar)
IL (1) IL290034A (ar)
JO (1) JOP20220030A1 (ar)
MX (1) MX2022001896A (ar)
WO (1) WO2021034639A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
WO2023077053A2 (en) 2021-10-28 2023-05-04 Regeneron Pharmaceuticals, Inc. Crispr/cas-related methods and compositions for knocking out c5
WO2024026386A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibody formulations
WO2024026395A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease
CN116712390B (zh) * 2023-08-04 2023-11-14 上海览屹医药科技有限公司 一种高浓度高稳定性的抗体制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
JP4656675B2 (ja) 1997-05-14 2011-03-23 ユニバーシティー オブ ブリティッシュ コロンビア 脂質小胞への荷電した治療剤の高率封入
EP2314690A1 (en) 2002-07-10 2011-04-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA-interference by single-stranded RNA molecules
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
WO2007092772A2 (en) * 2006-02-03 2007-08-16 Medimmune, Inc. Protein formulations
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
SG10201405377XA (en) 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
HUE056773T2 (hu) 2009-06-10 2022-03-28 Arbutus Biopharma Corp Továbbfejlesztett lipid készítmény
KR20230162998A (ko) 2013-03-14 2023-11-29 알닐람 파마슈티칼스 인코포레이티드 보체 성분 Ｃ5 ｉＲＮＡ 조성물 및 그 이용 방법
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
EP3119802B1 (en) 2014-03-20 2019-12-04 InflaRx GmbH Inhibitors of c5a for the treatment of viral pneumonia
EP3464351A1 (en) 2016-06-07 2019-04-10 Novartis AG Anti-c5 antibody for treating patients with complement c5 polymorphism
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
MA46466A (fr) * 2016-10-06 2019-08-14 Amgen Inc Formulations pharmaceutiques de protéines à viscosité réduite
CN116271012A (zh) * 2017-07-27 2023-06-23 瑞颂医药公司 高浓度抗c5抗体制剂
US20200254092A1 (en) * 2017-10-26 2020-08-13 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
KR20200098528A (ko) * 2017-12-13 2020-08-20 리제너론 파아마슈티컬스, 인크. 항-c5 항체 조합물 및 이의 용도

Also Published As

Publication number Publication date
CN116782876A (zh) 2023-09-19
EP4013784A1 (en) 2022-06-22
MX2022001896A (es) 2022-06-02
US20210046182A1 (en) 2021-02-18
AU2020334880A1 (en) 2022-03-24
WO2021034639A1 (en) 2021-02-25
CO2022001097A2 (es) 2022-03-08
CA3145621A1 (en) 2021-02-25
CL2022000340A1 (es) 2022-10-07
IL290034A (en) 2022-03-01
BR112022002831A2 (pt) 2022-06-28
KR20220047826A (ko) 2022-04-19
WO2021034639A4 (en) 2021-04-15
JP2022544589A (ja) 2022-10-19

Similar Documents

Publication Publication Date Title
MX2022001896A (es) Formulaciones anti-c5 de alta concentracion.
EA201590388A1 (ru) Способы лечения таупатии
CL2021000458A1 (es) Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr (divisional de solicitud 201602359)
PH12019500668A1 (en) Anti-lag-3 antibodies and compositions
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2022012749A (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
EA201592203A1 (ru) Способы лечения таупатии
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
EA202190226A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ HFpEF С ИСПОЛЬЗОВАНИЕМ ДАПАГЛИФЛОЗИНА И СОДЕРЖАЩИХ ЕГО КОМПОЗИЦИЙ
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.